Vera Therapeutics (NASDAQ:VERA) CEO Marshall Fordyce Sells 18,500 Shares of Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 18,500 shares of the firm’s stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $37.93, for a total value of $701,705.00. Following the completion of the sale, the chief executive officer directly owned 198,244 shares in the company, valued at $7,519,394.92. This trade represents a 8.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Marshall Fordyce also recently made the following trade(s):

• On Tuesday, May 12th, Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock. The stock was sold at an average price of $36.74, for a total value of $679,690.00.
• On Tuesday, April 14th, Marshall Fordyce sold 22,951 shares of Vera Therapeutics stock. The stock was sold at an average price of $44.05, for a total transaction of $1,010,991.55.

Vera Therapeutics Stock Up 3.4%

VERA stock opened at $39.51 on Thursday. The firm has a 50-day moving average price of $36.16 and a 200-day moving average price of $41.50. Vera Therapeutics, Inc. has a 12 month low of $19.07 and a 12 month high of $56.05. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $2.84 billion, a P/E ratio of -7.13 and a beta of 0.93.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same quarter in the prior year, the company earned ($0.81) EPS. As a group, equities research analysts anticipate that Vera Therapeutics, Inc. will post -6.23 EPS for the current fiscal year.

Hedge Funds Weigh In On Vera Therapeutics

Several large investors have recently modified their holdings of VERA. Price T Rowe Associates Inc. MD grew its stake in shares of Vera Therapeutics by 49.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,461,976 shares of the company’s stock worth $276,595,000 after purchasing an additional 1,795,537 shares during the last quarter. Deerfield Management Company L.P. grew its position in shares of Vera Therapeutics by 8.8% in the 3rd quarter. Deerfield Management Company L.P. now owns 3,641,157 shares of the company’s stock valued at $105,812,000 after buying an additional 293,040 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Vera Therapeutics by 11.9% in the 4th quarter. Vanguard Group Inc. now owns 3,570,401 shares of the company’s stock valued at $180,805,000 after buying an additional 379,748 shares during the last quarter. Vestal Point Capital LP increased its stake in shares of Vera Therapeutics by 24.0% in the second quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock valued at $73,036,000 after buying an additional 600,000 shares during the period. Finally, Eversept Partners LP increased its stake in shares of Vera Therapeutics by 9.4% in the fourth quarter. Eversept Partners LP now owns 3,072,304 shares of the company’s stock valued at $155,581,000 after buying an additional 264,468 shares during the period. Institutional investors own 99.21% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on VERA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Monday, April 20th. Jefferies Financial Group restated a “buy” rating and set a $60.00 price objective on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Wolfe Research raised Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 target price for the company in a report on Wednesday, March 11th. Evercore set a $91.00 target price on Vera Therapeutics in a research report on Friday, May 15th. Finally, HC Wainwright lifted their price target on Vera Therapeutics from $90.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $78.00.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.